Lipopolysaccharide (LPS) is a major cell wall component of Gram-negative bacteria and signals through a receptor complex which consists of TLR4, MD-2 and CD14. LPS signaling in macrophages induces the production of many pro-inflammatory molecules, including nitric oxide (NO). In this study, we have shown that folimycin, a macrolide antibiotic and a specific inhibitor of vacuolar ATPase (V-ATPase), inhibits LPS-induced NO production, but not TNFα production, in murine elicited peritoneal macrophages. However, folimycin did not affect interferon-γ induced NO production. LPS-induced iNOS mRNA and protein expression and NF-κB activation were also inhibited by folimycin. Interestingly, folimycin-treated cells showed reduced surface expression of TLR4 molecules and dilated Golgi apparatus. These findings suggest that folimycin, by inhibiting V-ATPases, alters intra-Golgi pH, which in turn causes defective processing and reduced surface expression of TLR4 reducing the strength of LPS signaling in murine macrophages.
Annane D., Bellissant E., Cavaillon J-M.Septic shock. Lancet2005; 365: 63—78.
2.
Medzhitov R. , Preston-Hurlburt P., Janeway Jr CA. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity . Nature1997; 388: 394—397.
3.
Poltorak A., He X., Smirnova I. et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science1998; 282: 2085—2088.
4.
Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JCCD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science1990; 249: 1431—1433.
5.
Shimazu R., Akashi S., Ogata H. et al. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med1999; 189: 1777—1782.
6.
Nagai Y., Akashi S., Nagafuku M. et al. Essential role of MD-2 in LPS responsiveness and TLR4 distribution . Nat Immunol2002; 3: 667—672.
7.
Hoshino K., Takeuchi O., Kawai T. et al. Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol1999; 162: 3749—3752.
8.
Alderton WK, Cooper CE, Knowles RGNitric oxide synthases: structure, function and inhibition. Biochem J2001; 357: 593—615.
9.
Aktan F.iNOS-mediated nitric oxide production and its regulation. Life Sci2004; 75: 639—653.
10.
Bogdan C.Nitric oxide and the immune response. Nat Immunol2001; 2: 907—916.
11.
Fitzgerald KA, Chen ZJSorting out Toll signals. Cell2006; 125: 834—836.
12.
Hayden MS, West AP, Ghosh S.NF-kappaB and the immune response. Oncogene2006; 25: 6758—6780.
13.
Drose S., Bindseil KU, Bowman EJ, Siebers A., Zeeck A., Altendorf K.Inhibitory effect of modified bafilomycins and concanamycins on P- and V-type adenosine triphosphatases. Biochemistry1993 ; 32: 3902—3906.
14.
de Bouteiller O., Merck E., Hasan UA et al. Recognition of double-stranded RNA by human Toll-like receptor 3 and downstream receptor signaling requires multimerization and an acidic pH. J Biol Chem2005; 280: 38133—38145.
15.
Lee J., Chuang TH, Redecke V. et al. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc Natl Acad Sci USA2003; 100: 6646—6651.
16.
Rutz M., Metzger J., Gellert T. et al. Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur J Immunol2004 ; 34: 2541—2550.
17.
Yilla M., Tan A., Ito K., Miwa K., Ploegh HLInvolvement of the vacuolar H(+)-ATPases in the secretory pathway of HepG2 cells. J Biol Chem1993; 268: 19092—19100.
18.
Weisz OAAcidification and protein traffic. Int Rev Cytol2003; 226: 259—319.
19.
Mellman I., Fuchs R., Helenius A.Acidification of the endocytic and exocytic pathways. Annu Rev Biochem1986; 55: 663—700.
20.
Muroi M., Shiragami N., Nagao K., Yamasaki M., Takatsuki A.Folimycin (concanamycin A), a specific inhibitor of V-ATPase, blocks intracellular translocation of the glycoprotein of vesicular stomatitis virus before arrival to the Golgi apparatus. Cell Struct Funct1993; 18: 139—149.
21.
Muroi M., Takasu A., Yamasaki M., Takatsuki A.Folimycin (concanamycin A), an inhibitor of V-type H(+)-ATPase, blocks cell-surface expression of virus-envelope glycoproteins. Biochem Biophys Res Commun1993; 193: 999—1005.
22.
Green LC, Wagner DA, Glogowski J., Skipper PL, Wishnok JS, Tannenbaum SRAnalysis of nitrate, nitrite, and [15N]-nitrate in biological fluids . Anal Biochem1982; 126: 131—138.
23.
Muroi M., Shiragami N., Takatsuki A.Destruxin B, a specific and readily reversible inhibitor of vacuolar-type H(+)-translocating ATPase. Biochem Biophys Res Commun1994; 205: 1358—1365.
24.
Hong J., Nakano Y., Yokomakura A. et al. Nitric oxide production by the vacuolar-type (H+)-ATPase inhibitors bafilomycin A1 and concanamycin A and its possible role in apoptosis in RAW 264.7 cells. J Pharmacol Exp Ther2006; 319: 672—681.
25.
Drouet C., Shakhov AN, Jongeneel CVEnhancers and transcription factors controlling the inducibility of the tumor necrosis factor-alpha promoter in primary macrophages. J Immunol1991; 147: 1694—1700.
26.
Seog DHSS33410, an inhibitor of V-ATPase, blocks intracellular protein transport of the VSV-G protein in the Golgi compartment. Biosci Biotechnol Biochem2003; 67: 2591—2597.
27.
Seog DH, Yamasaki M., Takatsuki A.SS33410, an inhibitor for inflammation, blocks the intracellular transport of VSV G glycoprotein in BHK cells. Biochem Biophys Res Commun1994; 199: 1073—1080.
28.
Akashi S., Shimazu R., Ogata H. et al. Cell surface expression and lipopolysaccharide signaling via the Toll-like receptor 4—-MD-2 complex on mouse peritoneal macrophages . J Immunol2000; 164: 3471—3475.
29.
Nomura F., Akashi S., Sakao Y. et al. Endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface Toll-like receptor 4 expression. J Immunol2000; 164: 3476—3479.
30.
Gustafson CE , Katsura T., McKee M., Bouley R., Casanova JE, Brown D.Recycling of AQP2 occurs through a temperature- and bafilomycin-sensitive trans-Golgi-associated compartment. Am J Physiol2000; 278: F317—F326.
31.
Palokangas H., Metsikko K., Vaananen K.Active vacuolar H+-ATPase is required for both endocytic and exocytic processes during viral infection of BHK-21 cells . J Biol Chem1994; 269: 17577—17585.
32.
Robinson DG , Albrecht S., Moriysu Y.The V-ATPase inhibitors concanamycin A and bafilomycin A lead to Golgi swelling in tobacco BY-2 cells . Protoplasma2004; 224: 255—260.
33.
Zhang X., Morrison DCLipopolysaccharide-induced selective priming effects on tumor necrosis factor α and nitric oxide production in mouse peritoneal macrophages. J Exp Med1993; 177: 511—516.
34.
Zhang X., Morrison DCPertussis toxin-sensitive factor differentially regulates lipopolysaccharide-induced tumor necrosis factor-alpha and nitric oxide production in mouse peritoneal macrophages. J Immunol1993; 150: 1011—1018.
35.
Hirohashi N. , Lei MG, Morrison DCLPS pretreatment of mouse peritoneal macrophages differentially modulates TNF-α and iNOS expression . J Endotoxin Res1999; 5: 251—260.
Schapiro FB , Grinstein S.Determinants of the pH of the Golgi complex . J Biol Chem2000; 275: 21025—21032.
39.
Presley JF, Mayor S., McGraw TE, Dunn KW, Maxfield FRBafilomycin A1 treatment retards transferrin receptor recycling more than bulk membrane recycling. J Biol Chem1997; 272: 13929—13936.
40.
Tawfeek HA, Abou-Samra ABImportant role for the V-type H(+)-ATPase and the Golgi apparatus in the recycling of PTH/PTHrP receptor. Am J Physiol2004; 286: E704—E710.
41.
Palokangas H. , Ying M., Vaananen K., Saraste J.Retrograde transport from the pre-Golgi intermediate compartment and the Golgi complex is affected by the vacuolar H+-ATPase inhibitor bafilomycin A1. Mol Biol Cell1998; 9: 3561—3578.
42.
Johnson LS, Dunn KW, Pytowski B., McGraw TEEndosome acidification and receptor trafficking: bafilomycin A1 slows receptor externalization by a mechanism involving the receptor's internalization motif . Mol Biol Cell1993; 4: 1251—1266.
43.
da Silva Correia J., Ulevitch RJMD-2 and TLR4 N-linked glycosylations are important for a functional lipopolysaccharide receptor. J Biol Chem2002; 277: 1845—1854.
44.
Ohnishi T., Muroi M., Tanamoto K.N-linked glycosylations at Asn(26) and Asn(114) of human MD-2 are required for Toll-like receptor 4-mediated activation of NF-kappaB by lipopolysaccharide . J Immunol2001; 167: 3354—3359.
45.
Stelter F., Pfister M., Bernheiden M. et al. The myeloid differentiation antigen CD14 is N- and O-glycosylated. Contribution of N-linked glycosylation to different soluble CD14 isoforms . Eur J Biochem1996; 236: 457—464.
46.
Kellokumpu S., Sormunen R., Kellokumpu I.Abnormal glycosylation and altered Golgi structure in colorectal cancer: dependence on intra-Golgi pH. FEBS Lett2002; 516: 217—224.
47.
Annane D., Sanquer S., Sebille V. et al. Compartmentalised inducible nitric-oxide synthase activity in septic shock. Lancet2000; 355: 1143—1148.
48.
Han X., Fink MP, Yang R., Delude RLIncreased iNOS activity is essential for intestinal epithelial tight junction dysfunction in endotoxemic mice. Shock2004 ; 21: 261—270.
49.
Nava E., Palmer RM, Moncada S.Inhibition of nitric oxide synthesis in septic shock: how much is beneficial ? Lancet1991; 338: 1555—1557.
50.
Lopez A., Lorente JA, Steingrub J. et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med2004; 32: 21—30.
